NEW YORK (GenomeWeb News) – ChondroGene today said it has received “conditional approval” from Canadian regulators to list its common shares on the Toronto Stock Exchange.
 
The company, which must still file final documentation, said it expects to begin trading its common shares on the TSX by Oct. 31.
 
At that time ChondroGene will change its name to GeneNews and will trade under the symbol GEN, and ChondroGene’s common shares will cease trading on the TSX Venture Exchange.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.